LEADER 02775nam  2200409z- 450 
001 9910743275903321
005 20230911
035   $a(CKB)5690000000228549
035   $a(oapen)doab113867
035   $a(EXLCZ)995690000000228549
100   $a20230920c2023uuuu  -u-         -
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aInfection, Super Infection and Antimicrobial Management in ICU
210   $cMDPI - Multidisciplinary Digital Publishing Institute$d2023
215   $a1 online resource (144 p.)
311 08$a3-0365-8381-5 
330   $aAssessing the risk of difficult-to-treat bacterial superinfections, such as multidrug-resistant (MDR) Gram-negative bacilli, according to comorbidities, lung abnormalities or systemic diseases, the severity of pneumonia and the risks of drug-related effects are crucial points for the clinical management. Despite the wide-and not always appropriate-use of broad-spectrum antimicrobials, specific data about bacterial and fungal co-infection in COVID-19 patients are lacking, and confirmed evidence is urgently required to build prospective evidence and to support the development of antimicrobial policy and appropriate stewardship interventions. The present Special Issue aims to focus on the following key points: Importance of superinfections in COVID-19 patients who are typically characterized by immunosuppression related to viral infection, need for prolonged hospitalization, treatment with immunomodulatory therapies (steroids, monoclonal antibodies, etc.); Their impact on the outcome of a cohort of patients who are relatively young, with few comorbidities, but requiring prolonged invasive support; Incidence, characteristics and impact of bacterial infections caused by multidrug-resistant, Gram-negative pathogens in the context of COVID-19 disease; Incidence, characteristics and impact of fungal infections, such as the most known invasive aspergillosis but also candidemia and/or other fungal infections (e.g., mucormycosis); Antimicrobial surveillance, control and management measures as implemented on a local, national and international basis.
606   $aMedicine$2bicssc
610   $aantimicrobial resistance
610   $aantimicrobial stewardship
610   $abacterial infections
610   $aCOVID-19
610   $acritical care medicine
610   $afungal infections
610   $aintensive care medicine
610   $amultidrug-resistant pathogens
610   $aSARS-CoV-2
610   $aSuperinfections
615  7$aMedicine
906   $aBOOK
912   $a9910743275903321
996   $aInfection, Super Infection and Antimicrobial Management in ICU$93560555
997   $aUNINA